Section Arrow
AIM.NYSE-M
- AIM ImmunoTech Inc
Quotes are at least 15-min delayed:2025/06/18 15:12 EDT
Last
 8.45
-1.7 (-16.75%)
Day High 
10.0263 
Prev. Close
10.15 
1-M High
14.93 
Volume 
17.38K 
Bid
8.25
Ask
8.54
Day Low
8.2 
Open
9.58 
1-M Low
5.8 
Market Cap 
726.03M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 7.82 
20-SMA 7.99 
50-SMA 7.1 
52-W High 42.95 
52-W Low 2.51 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-24.00/-31.00
Enterprise Value
726.03M
Balance Sheet
Book Value Per Share
-5.05
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
170.00K
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
APVOAptevo Therapeutics Inc5.43+2.61+92.55%0PE
NCNANuCana plc0.1249+0.0013+1.05%-- 
RXRXRecursion Pharmaceuticals5.0854+0.2454+5.07%-- 
BDRXBiodexa Pharmaceuticals plc1.05+0.2537+31.86%-- 
PSTVPlus Therapeutics0.208-0.1006-32.60%-- 
Quotes are at least 15-min delayed:2025/06/18 15:12 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.